Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
BENICAR |
| Manufacturer |
|
Daiichi-Sankyo |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker. |
| Generic Name |
|
Olmesartan medoxomil 5mg, 20mg, 40mg; tabs. |
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Monotherapy, not volume-depleted: initially 20mg once daily; may increase to max 40mg once daily after 2 weeks. Volume depleted (eg, concomitant diuretic): consider lower initial dose. |
| Contraindications |
|
Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before beginning therapy, or monitor closely. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. |
| Adverse Reactions |
|
Dizziness, rhabdomyolysis (rare). |
| How Supplied |
Tabs 5mg—30
20mg, 40mg—30, 90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
